154 related articles for article (PubMed ID: 25604508)
1. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer.
Goumas FA; Holmer R; Egberts JH; Gontarewicz A; Heneweer C; Geisen U; Hauser C; Mende MM; Legler K; Röcken C; Becker T; Waetzig GH; Rose-John S; Kalthoff H
Int J Cancer; 2015 Sep; 137(5):1035-46. PubMed ID: 25604508
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice.
Egberts JH; Schniewind B; Pätzold M; Kettler B; Tepel J; Kalthoff H; Trauzold A
Cancer Biol Ther; 2008 Jul; 7(7):1044-50. PubMed ID: 18431088
[TBL] [Abstract][Full Text] [Related]
3. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.
Mochizuki D; Adams A; Warner KA; Zhang Z; Pearson AT; Misawa K; McLean SA; Wolf GT; Nör JE
Oncotarget; 2015 Sep; 6(26):22822-35. PubMed ID: 26287605
[TBL] [Abstract][Full Text] [Related]
5. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.
Egberts JH; Cloosters V; Noack A; Schniewind B; Thon L; Klose S; Kettler B; von Forstner C; Kneitz C; Tepel J; Adam D; Wajant H; Kalthoff H; Trauzold A
Cancer Res; 2008 Mar; 68(5):1443-50. PubMed ID: 18316608
[TBL] [Abstract][Full Text] [Related]
7. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.
Zhao W; Ajani JA; Sushovan G; Ochi N; Hwang R; Hafley M; Johnson RL; Bresalier RS; Logsdon CD; Zhang Z; Song S
Gastroenterology; 2018 Apr; 154(5):1524-1537.e6. PubMed ID: 29274868
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
10. The P2X7 Receptor Stimulates IL-6 Release from Pancreatic Stellate Cells and Tocilizumab Prevents Activation of STAT3 in Pancreatic Cancer Cells.
Magni L; Bouazzi R; Heredero Olmedilla H; Petersen PSS; Tozzi M; Novak I
Cells; 2021 Jul; 10(8):. PubMed ID: 34440697
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.
Bausch D; Pausch T; Krauss T; Hopt UT; Fernandez-del-Castillo C; Warshaw AL; Thayer SP; Keck T
Angiogenesis; 2011 Sep; 14(3):235-43. PubMed ID: 21442180
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
Awasthi N; Mikels-Vigdal AJ; Stefanutti E; Schwarz MA; Monahan S; Smith V; Schwarz RE
J Cell Mol Med; 2019 Jun; 23(6):3878-3887. PubMed ID: 30941918
[TBL] [Abstract][Full Text] [Related]
13. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
14. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
15. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model.
Barkhausen T; Tschernig T; Rosenstiel P; van Griensven M; Vonberg RP; Dorsch M; Mueller-Heine A; Chalaris A; Scheller J; Rose-John S; Seegert D; Krettek C; Waetzig GH
Crit Care Med; 2011 Jun; 39(6):1407-13. PubMed ID: 21336117
[TBL] [Abstract][Full Text] [Related]
16. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
17. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
18. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
19. A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma.
Joensson P; Hotz B; Buhr HJ; Hotz HG
Langenbecks Arch Surg; 2011 Apr; 396(4):535-41. PubMed ID: 21404005
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
